"Long-term eltrombopag demonstrated efficacy in restoring platelet counts and decreasing risk of bleeding in patients with chronic/persistent immune thrombocytopenia (ITP) lasting more than 6 months, according to a study published in Blood.
Previous studies demonstrated that eltrombopag treatment for 6 months or less effectively increased platelet counts and reduced bleeding in patients with chronic ITP. The purpose of this analysis was to evaluate the safety and efficacy of long term therapy with eltrombopag."
- By James Nam, PharmD. Photo courtesy OncologyNurseAdvisor.com.